RE: Their compounds do look promising16 May 2018 11:58
I do apologize - I've now improved the grammar:
It's a compelling, potential-therapeutic portfolio, Apple. Poor decision making regarding funding by the board is why the price has slipped to these basement prices. At �12M MCap there is potentially a lot of upside from such levels.A good positive RNS could easily see this sail past 4p. Bio-Pharma partnering or JV and yes sky is the limit IMO.